In the first seven weeks of 2026, two companies committed more than $4.5 billion to new life sciences manufacturing plants in eastern Pennsylvania. Next week, on September 30 and October 1, the ecosystem that attracted that money holds its annual meeting, Life Sciences Future 2026, at the Sheraton Valley Forge in King of Prussia. Most of the room will be there for capital, science, and partnerships. All three run on the same scarce resource, and it is not money.
Life Sciences Future is hosted by Life Sciences Pennsylvania, the statewide trade association that now represents more than 960 member companies. The room reflects that membership: biotech and diagnostics companies, medical device makers, pharmaceutical manufacturers, research institutions, investors, and the service firms that support all of them. The format is built for dealmaking. There is a one-on-one partnering system for scheduling meetings, panel discussions, company presentations with pitch decks, exhibitor showcases, and reverse pitches, where investors and strategic organizations get on stage and describe what they want to fund. This year’s co-chairs include Jeff Dayno, the president and CEO of Harmony Biosciences, a commercial-stage Pennsylvania drug company, which says something in itself about how far the state’s homegrown companies have come.
RX2 Solutions is based in Paoli, a short drive from the venue, so this is our home ecosystem’s annual meeting. Most attendees will walk in thinking about capital, pipelines, and partnerships. We read the same event through a different lens. Every financing announced from that stage, every facility groundbreaking mentioned on a panel, and every startup working the partnering system converts into the same downstream question: who is going to do the work? Read that way, the event is a two-day preview of hiring demand in our region.
As of this writing, the detailed 2026 agenda is still being finalized, so we will not guess at session titles. We do not need to. The verifiable numbers behind the event tell the talent story on their own.
The ecosystem in the room, by the numbers
Start with the state. Pennsylvania’s life sciences industry employs more than 100,000 people across nearly 3,100 companies, according to the state Department of Community and Economic Development, and companies here secured more than 10,700 life sciences patents over the past five years, the fourth highest total in the country. The industry’s own economic impact study, commissioned by Life Sciences Pennsylvania and conducted by KPMG, estimated the sector supports roughly 230,000 additional jobs beyond direct employment, and counted a nearly 17 percent increase in life sciences establishments between 2015 and 2020. Pennsylvania researchers also pulled in more than $2 billion in NIH funding in a single year.
Zoom into the Philadelphia region, where the conference sits, and the density increases. CBRE’s market profile counts about 55,000 life sciences workers in the metro area, which is 2.2 percent of regional employment against a national average of 1.4 percent. Nearly 19,000 of those people work in research and development roles. The region holds 11.6 million square feet of lab and R&D space with another 1.4 million under construction, and local companies raised more than $6.5 billion in venture funding between 2019 and 2024. In CBRE’s 2025 national talent rankings, Philadelphia moved past San Diego to become the seventh largest life sciences R&D talent market in the country.
Then there is the specialty that made the region famous. Greater Philadelphia is home to 60 of the roughly 500 cell and gene therapy companies in the world, per the Chamber of Commerce for Greater Philadelphia, and ranks as the second largest CGT hub in the nation, first in NIH gene therapy funding. More than 7,000 people already work in the field locally, nearly 10,000 across the wider 11-county region, and the Chamber’s benchmark study projects that workforce could grow between 35 and 94 percent by 2030. About $8 billion of the $18.7 billion raised by regional life sciences companies since 2018 is tied to cell and gene therapy.
Here is why those numbers matter for anyone who hires. Nationally, life sciences employment hit a record 2.1 million earlier in 2025, and unemployment in life sciences occupations was running around 3.1 percent, per CBRE. A dense cluster with above-average concentration and near-full employment means most of the people you want to hire already have jobs a few exits away on the turnpike. Growth in a market like this is not absorbed by idle talent. It is fought over.
The funding climate sets the hiring tempo
Follow the money at any life sciences conference and you are really following next year’s headcount. The 2026 funding picture is stronger than it has been in several years, but it is strong in a specific and uneven way.
Venture-backed biotechs raised more than $9.1 billion in the first half of 2026, the best first half since 2022, according to BioPharma Dive’s tracking. Thirteen biotechs went public and raised a combined $4.5 billion, and 38 acquisitions closed, the sector’s fastest deal pace in seven years. That is real fuel, and some of it will be on display in King of Prussia, both on the company presentation stage and in the reverse pitch sessions where investors describe what they want to back next.
The unevenness is the part hiring leaders should study. About 76 percent of those venture dollars came through megarounds of $100 million or more, and roughly two thirds of rounds went to companies already testing drugs in humans. Capital is crowding into clinical-stage and commercial-stage companies while early-stage startups and first-time founders find seed money harder to raise than it was five years ago.
For talent planning, that split translates cleanly. The companies with big rounds will hire fast and in volume: clinical operations, regulatory affairs, quality, manufacturing, and the commercial roles that follow late-stage data. They can outbid smaller rivals and will recruit hard from the same regional pool. The lean early-stage companies will hire fewer people but need each one to carry more, which raises the stakes on every individual search. Both dynamics tighten the same market from different directions, and both types of company will be in the same hotel for two days.
Manufacturing is where the hiring gets real
If the funding sessions preview hiring at biotech companies, the manufacturing story previews hiring at scale, and Pennsylvania’s 2026 manufacturing news has been remarkable.
In January, Eli Lilly picked Fogelsville in Lehigh County for a $3.5 billion injectable medicine and device plant, one of the largest life sciences investments in state history. The company says the site will create 850 permanent jobs for engineers, scientists, operations personnel, and lab technicians, plus 2,000 construction jobs, with operations targeted for 2031. Three weeks later, Johnson & Johnson announced a cell therapy manufacturing facility in Lower Gwynedd, Montgomery County, at more than $1 billion, bringing 500 permanent biomanufacturing jobs and over 4,000 construction jobs. That plant sits about 30 minutes from the conference venue.
Two announcements, 1,350 permanent jobs, and more than $4.5 billion in committed capital, all within an hour or so of the Sheraton Valley Forge. And these are only the flagship projects. The point for talent strategy is timing: plants announced in 2026 start recruiting leadership and technical staff years before ribbon cuttings, which means the competition for quality directors, process engineers, validation specialists, and experienced technicians in eastern Pennsylvania begins now, not in 2031.
The ecosystem knows its technician pipeline is the weak link, and the workforce programs trying to fix it will have people in the room too. One example worth knowing: the Wistar Institute’s Biomedical Technician Training pre-apprenticeship, now 25 years old, trains community college students from six regional colleges and, more recently, adult career changers, who complete ten weeks of evening classes and then a ten to twelve week externship with a local employer. The program drew a fresh $600,000 grant from the William Penn Foundation in late 2025 to expand. Programs like this are small relative to the demand curve, which is exactly why employers who plug into them early get outsized value from them.
One more thing executives outside life sciences should not miss. This talent competition does not respect industry boundaries. The same region that needs biomanufacturing technicians also has manufacturers, defense suppliers, and service companies hunting for maintenance techs, quality specialists, process engineers, and operations leaders, and nationally, manufacturing alone may need 3.8 million new workers by 2033 with up to 1.9 million roles at risk of going unfilled, per Deloitte and The Manufacturing Institute. When a pharmaceutical plant in Lehigh County posts 850 openings, the ripple hits every plant, depot, and facility that fishes in the same labor pool. A life sciences boom is a regional wage and retention event for everyone.
How smart companies work an event like this
Most companies attend industry conferences for deals and visibility. The ones that get lasting value also work them for talent. Five moves worth planning before September 30.
Send people worth meeting, and brief them as recruiters. Your attendees are your employer brand for two days. Prep them with a clear, honest answer to “what is it like to work there,” and make sure they can describe your science and your growth plans in plain language. Candidates decide how they feel about companies in hallway conversations, not on career sites.
Use the partnering system for talent, not just deals. The one-on-one meeting tool exists to book investor and partner meetings, but nothing stops you from booking coffee with the head of a workforce program, a university tech transfer contact, or a leader you may want to hire in two years. Pipeline relationships compound. Start them before you have an opening.
Get to know the workforce programs directly. Wistar’s technician program, community college partnerships, and university career offices all have one thing in common: employers who engage early get first access to graduates. A 30-minute conversation at a conference can put you at the front of that line.
Watch the reverse pitches for a hiring forecast. When investors describe what they want to fund, they are also describing where hiring will spike 12 to 24 months out. If three funds say they want regional manufacturing and late-stage assets, plan for what that does to local salaries for quality and operations talent.
Follow up within two weeks. Conference connections decay fast. Sort your contacts into candidates, referral sources, and program partners, and put a next step on the calendar for each before the badge lanyards go in the drawer.
What this means for boards and CEOs
For leadership teams in and around Pennsylvania, three priorities fall out of this preview.
First, treat regional talent supply as a strategic variable, not an HR detail. The data says your labor market has above-average density, near-full employment, and two multi-billion dollar plants about to start recruiting. Ask your team for a real map of which roles that squeezes and what your retention exposure looks like, before the poaching calls start.
Second, put someone senior at the ecosystem table. Life Sciences Future, Chamber initiatives, and workforce boards are where the region decides how to grow its own talent. Companies that show up shape the pipeline. Companies that skip it hire from whatever is left.
Third, budget for the premium now. Record employment plus concentrated capital equals rising pay for scarce skills. Boards that approve compensation ranges in January based on last year’s market will watch searches fail by June.
The Pennsylvania life sciences story heading into this year’s meeting is unusually good: record funding halves, a top-ten talent market, a world-class cell and gene therapy cluster, and billions in new manufacturing. Every part of that story runs through people. The companies that leave King of Prussia with a sharper talent plan will be the ones that turn the region’s momentum into their own.
RX2 Solutions is a workforce solutions firm specializing in HR outsourcing, executive search, and strategic staffing. We partner with organizations to build high-performing teams through customized talent strategies, leadership placement, and scalable workforce solutions.
📞 Phone: 610.340.3490
📧 Email: info@rx2solutions.com
🌐 Website: www.rx2solutions.com
RX2 Solutions
A Respectfully Professional People Company
Get the next one of these.
We publish one piece a week on hiring, HR, and leadership in regulated industries. Written by the people running the searches.
One email a week. Unsubscribe in one click. Your address stays with us.
Working on this problem right now?
Talk to a Managing Partner. You will hear back within one business day.
Start a Conversation